Supernus Pharm (SUPN) Posts Mixed Q2 Results

Supernus Pharm (NASDAQ: SUPN) reported Q2 EPS of ($5.17), $4.71 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $750 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Supernus Pharm (SUPN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• SuperCom (SPCB) Tops Q3 EPS by 43c
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation